1. Home
  2. FKWL vs BOLD Comparison

FKWL vs BOLD Comparison

Compare FKWL & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Wireless Corp.

FKWL

Franklin Wireless Corp.

HOLD

Current Price

$2.94

Market Cap

37.3M

Sector

Utilities

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.45

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FKWL
BOLD
Founded
1981
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
37.3M
36.5M
IPO Year
1997
2024

Fundamental Metrics

Financial Performance
Metric
FKWL
BOLD
Price
$2.94
$1.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$6.00
$4.00
AVG Volume (30 Days)
39.7K
127.7K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
1.10%
N/A
EPS Growth
94.12
32.47
EPS
N/A
N/A
Revenue
$46,086,901.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
49.65
N/A
52 Week Low
$2.88
$0.96
52 Week High
$5.48
$1.68

Technical Indicators

Market Signals
Indicator
FKWL
BOLD
Relative Strength Index (RSI) 34.43 50.05
Support Level N/A $1.40
Resistance Level $4.42 $1.55
Average True Range (ATR) 0.14 0.08
MACD -0.02 -0.01
Stochastic Oscillator 23.62 34.15

Price Performance

Historical Comparison
FKWL
BOLD

About FKWL Franklin Wireless Corp.

Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: